Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges - review article. | Ann Hematol;2023 Oct 23. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges - review article.

Youssry, Ilham; Ayad, Nardeen.

Affiliation

Youssry I; Pediatric Hematology and BMT Unit, Faculty of Medicine, Cairo University, Cairo, Egypt.
Ayad N; Pediatric Hematology and BMT Unit, Faculty of Medicine, Cairo University, Cairo, Egypt. nardeen.e.ayad@gmail.com.

Ann Hematol ; 2023 Oct 23.

Article in En | MEDLINE | ID: mdl-37867187

Key words

CRISPR; Crizanlizumab; L-Glutamine; Pyruvate kinase inhibitor; Sickle cell disease; Voxelotor

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: Egipto Country of publication: Alemania

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: Egipto Country of publication: Alemania